Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

RAISE: Recombinant Antivenoms for Intervention of Snakebite

Project description

World’s first recombinant snakebite antivenom

Currently, the therapy of choice for venomous snake bites is purified immunoglobulin preparations sourced from ‘hyperimmunised’ large animals such as horses and sheep. Although these preparations save lives, there is an urgent need for safer, more effective and broadly applicable therapies. The ERC-funded RAISE project aims to bring the world’s first recombinant snakebite antivenom to market. Relying on their previously developed oligoclonal mixture of neutralising antibodies that has shown promise in rodent models. The team plans to conduct pharmacokinetic studies in a large animal model to guide first-in-human trials. RAISE partners will also investigate regulatory and clinical trial pathways in affected countries and develop a business plan to bring an improved snakebite envenoming therapy to patients.

Objective

Snakebite envenoming is a neglected tropical disease that causes over 100,000 deaths and claims 6 million disability-adjusted life years annually. Plasma-derived antivenoms are life-saving but face major limitations, including high cost, batch variability, narrow species coverage, risk of severe adverse reactions, and poor efficacy against local tissue damage. Safer, more effective, and broadly neutralizing therapies are urgently needed.

RAISE will advance the world’s first recombinant snakebite antivenom. My team and I have developed an oligoclonal mixture of eight broadly neutralizing nanobodies that reduces local tissue damage and protects against lethality from 17 of the most medically relevant African elapids in mice (Ahmadi et al. Nature 2025). However, rodent models poorly predict human pharmacokinetics, making large-animal models essential for generating translational data on circulation, distribution, and toxin-neutralizing properties.

In RAISE we will: (i) conduct pharmacokinetic studies in a large animal model, comparing monomeric and half-life-extended nanobody constructs to generate data that will guide product design, dosing, and regulatory dialogue for first-in-human trials; (ii) map regulatory and clinical trial pathways in relevant geographies, benchmarking against EMA, FDA, and WHO prequalification requirements while aligning with Target Product Profiles (TPPs); and (iii) develop a business plan covering market and pricing analysis, go-to-market strategy, growth opportunities with partners and investors, exit strategies, and intellectual property strategies.

By addressing critical scientific, regulatory, and business uncertainties, RAISE will de-risk the path to clinical translation and lay the foundation for a spin-out company. In doing so, we will RAISE the standard of care and improve access to safe, effective, and affordable recombinant antivenoms for snakebite victims.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

DANMARKS TEKNISKE UNIVERSITET
Net EU contribution
€ 150 000,00
Address
ANKER ENGELUNDS VEJ 101
2800 Kongens Lyngby
Denmark
Region
Danmark Hovedstaden Københavns omegn
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)